NCT05486767

Screening of Liver Fibrosis in Adults Without Known Liver Disease

Screening of Liver Fibrosis in Adults Without Known Liver Disease or With Previously Diagnosed Non-alcoholic Fatty Liver Disease

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

SIRIUS is the "serious" response to the prevalence of liver cirrhosis in Slovakia. We plan to screen adult Slovaks without acute or life-threatening comorbidity and without known liver disease (except from non-alcoholic fatty liver disease) for liver fibrosis by transient elastography (in community) or FIB-4 score (in outpatient clinics).

Detailed description

According to the Lancet Gastroenterology and Hepatology, Slovakia ranks at the top of the prevalence of liver cirrhosis in the world. Moreover, liver diseases are the leading cause of death in the age-group of 25 - 50 years-old. SIRIUS is the response conceived by the governing board of the Slovak society of hepatology with two main aims: to screen for liver fibrosis and to spread the largely unknown information in community, and primary-care sector.

Conditions

• Liver Fibrosis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Transient elastography	Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)

Timeline

• Start date: 2022-08-28
• Primary completion: 2023-09-01
• Completion: 2023-12-30
• First posted: 2022-08-04
• Last updated: 2022-08-05

Locations

3 sites across 1 country: Slovakia